An interventional study of Physiotherapy and Sham Osteopathy in Dupuytren Disease, sponsored by Clinique Bizet. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Clinique Bizet · Not applicable, Interventional, and Treatment
This randomized, double-blind clinical trial evaluates whether adding targeted osteopathy to physiotherapy improves recovery after open surgery for Dupuytren disease.
Patients who have undergone their first open fasciectomy for Dupuytren disease will be randomly assigned to one of two groups. Both groups will receive physiotherapy. One group will additionally receive a targeted osteopathy session, while the other group will receive a sham osteopathy session.
The main objective is to evaluate recovery of extension of the metacarpophalangeal joint of the operated finger. Secondary outcomes include hand function, extension of the proximal and distal interphalangeal joints, grip strength, scar vascularization, quality of life, scar adherence, and postoperative pain.
The study will include 50 adult patients. Participants will be followed for 12 weeks, with assessments at 1, 4, 8, and 12 weeks after the start of treatment.
Dupuytren disease is a chronic fibroproliferative condition of the hand characterized by progressive fibrosis of the palmar aponeurosis, which can lead to nodules, fibrous cords, digital retractions, and contractures. These deformities may impair hand function and daily activities and may affect quality of life.
For advanced stages of the disease, open fasciectomy is a surgical treatment. Although surgery generally allows recovery of finger extension, postoperative recovery may be prolonged and may be associated with persistent inflammation, scar adhesions, altered tissue gliding, and temporary reductions in mobility and strength.
The purpose of this pilot randomized controlled trial is to evaluate the potential benefit of adding osteopathy to conventional postoperative physiotherapy following open fasciectomy for Dupuytren disease. According to the study protocol, the benefits of osteopathy in this specific postoperative context have not previously been evaluated in a prospective randomized controlled trial.
After eligibility has been confirmed and informed consent has been obtained, participants will be randomly assigned to one of two groups. Both groups will receive physiotherapy as part of postoperative care. The experimental group will receive a targeted osteopathy session, while the control group will receive a sham osteopathy session. Physiotherapy and osteopathy sessions are planned to take place on the same day when possible. A gentle night extension splint will be applied on postoperative day 8 according to the usual protocol.
The primary outcome is recovery of extension of the metacarpophalangeal joint of the operated finger, assessed by goniometry at 1, 4, 8, and 12 weeks after the start of treatment.
Secondary outcomes include hand function assessed using the Unité Rhumatologique des Affections de la Main (URAM) score; extension of the proximal and distal interphalangeal joints assessed by goniometry; grip strength assessed using a hand dynamometer; scar vascularization assessed using an infrared camera (FLIR ONE Pro); hand-related quality of life assessed using the Brief Michigan Hand Outcomes Questionnaire (Brief MHQ); scar adherence assessed using an adhesiometer; and postoperative pain assessed using the Visual Analog Scale (VAS). These outcomes will be assessed at 1, 4, 8, and 12 weeks after the start of treatment.
The planned sample size is 50 participants. The planned inclusion period is 15 months, with a 3-month follow-up for each participant and a total planned study duration of 18 months.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
This study's planned enrollment of 50 is below the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Browse Dupuytren Contracture studies →Clinique Bizet is the lead sponsor of 16 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive physiotherapy combined with targeted osteopathy.
Behavioral: Physiotherapy
Participants receive physiotherapy combined with sham osteopathy.
Behavioral: Sham Osteopathy
Physiotherapy
Sham osteopathy
MCP joint extension
Goniometric measurement of metacarpophalangeal (MCP) joint extension
Time frame: 1, 4, 8, and 12 weeks after treatment start
URAM score
Assessment of hand function using the Unité Rhumatologique des Affections de la Main (URAM) score.
Time frame: 1, 4, 8, and 12 weeks after treatment start
PIP and DIP joint extension
Goniometric measurement of proximal and distal interphalangeal joint extension.
Time frame: 1, 4, 8, and 12 weeks after treatment start
Grip strength
Measurement of grip strength using a hand dynamometer.
Time frame: 1, 4, 8, and 12 weeks after treatment start
Scar vascularization
Assessment of scar vascularization using a FLIR ONE Pro infrared camera.
Time frame: 1, 4, 8, and 12 weeks after treatment start
Brief Michigan Hand Questionnaire (Brief MHQ) score
Assessment of quality of life using the Brief Michigan Hand Questionnaire (Brief MHQ).
Time frame: 1, 4, 8, and 12 weeks after treatment start
Scar adherence
Assessment of scar adherence using an adhesiometer.
Time frame: 1, 4, 8, and 12 weeks after treatment start
Postoperative pain
Assessment of pain using a visual analog scale (VAS).
Time frame: 1, 4, 8, and 12 weeks after treatment start
Plan to share: No
Start is estimated for Sep 2026; primary completion for Sep 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Bizet